Africa’s leading drug manufacturer Aspen Pharmacare Holdings has reportedly agreed to acquire a unit of competitor Mereck & Co in a deal worth about $1 billion. In a statement, Aspen CEO Stephen Saad said the acquisition will aid his company’s output in Latin America and Asia, where the firm looks to strength its roots. According to reports, the agreement involves the buyout of a products unit, which uses molecules for therapeutic treatment including hormone replacement therapy and oral contraceptives. Aspen’s drugs unit is based in the Netherlands. The deal is the largest divestment made by Mereck since 2009.
Featured News
Former DOJ Antitrust Lawyer Returns to Sullivan & Cromwell
Jul 27, 2026 by
CPI
Trip.com Accepts $765 Million Antitrust Penalty as China Concludes Monopoly Investigation
Jul 27, 2026 by
CPI
Google Seeks to Exclude EU DMA Decision From Evidence in UK Shopping Damages Trial
Jul 27, 2026 by
CPI
Judge Allows Beef Price-Fixing Class Action to Move Toward Trial
Jul 27, 2026 by
CPI
Japanese Banks Combine Ship Finance Operations to Form $12.8B Maritime Lending Platform
Jul 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes